AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3559333
Drug: Regimen II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen II: same as Regimen I, supplemented with an additional 6 months' treatment with dapsone 100 mg daily
Trial: 3559333
Drug: Regimen III:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen III: same as Regimen II, with rifampin administered daily for the first 7 days
Trial: 31421394
Drug: 2.5% GS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% GS solution with 15% glucose
Trial: 31421394
Drug: 25 mL
RxNorm normalized name: ethanol 6.025 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mL of water (control) with 15% glucose
Trial: 31421394
Drug: 2.5% GS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% GS solution with 0.09% aspartame
Trial: 31421394
Drug: 25 mL
RxNorm normalized name: ethanol 6.025 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mL of water (control) with 0.09% aspartame
Trial: 15363053
Drug: Rapid intravenous
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid intravenous iron injection (100 mg of iron sucrose every 2 weeks)
Trial: 15363053
Drug: Slow intravenous
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow intravenous iron infusion (100 mg of iron sucrose every 2 weeks)
Trial: 15363053
Drug: Rapid intravenous
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid intravenous iron injection
Trial: 15363053
Drug: Slow intravenous
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow intravenous iron infusion
Trial: 8087930
Drug: C-type natriuretic
RxNorm normalized name: C-type natriuretic peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-type natriuretic peptide (CNP) infusion
Trial: 31265187
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy expert (treatment provider)
Trial: 25405570
Drug: BZA 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BZA 20 mg
Trial: 25405570
Drug: CE 0.45
RxNorm normalized name: Femtrace 0.45mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE 0.45 mg/BZA 20 mg and CE 0.625 mg/BZA 20 mg
Trial: 15466104
Drug: HEDIS criteria
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEDIS criteria sensitivity for children without daily controller medications
Trial: 15466104
Drug: HEDIS criteria
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEDIS criteria specificity for children without daily controller medications
Trial: 26400835
Drug: Buprenorphine/naloxone (BUP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone (BUP) induction dosing patterns
Trial: 23261733
Drug: Fluoxetine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine alone (Group A)
Trial: 23261733
Drug: Fluoxetine and
RxNorm normalized name: fluoxetine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine and Cognitive Behavioral Therapy (CBT) (Group B)
Trial: 15930064
Drug: Quality improvement
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quality improvement intervention with special resources for therapy
Trial: 15930064
Drug: Quality improvement
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quality improvement intervention with special resources for medication management
Trial: 14595996
Drug: T'ai Chi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T'ai Chi exercise (1-hour sessions, twice weekly for 6 weeks)
Trial: 10793607
Drug: Dimenhydrinate 50
RxNorm normalized name: dimenhydrinate 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimenhydrinate 50 mg administered rectally 30 min before anaesthesia
Trial: 8793254
Drug: Flurbiprofen LAT
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen LAT (40 mg b.d.)
Trial: 1740600
Drug: Daily supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplement of 560 +/- 16 kcal/day (17% energy from protein, 43% from carbohydrate, 40% from fat) during 12 weeks of resistance training.
Trial: 1740600
Drug: No supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplement during 12 weeks of resistance training.
Trial: 6442383
Drug: Oxazepam (OX)
RxNorm normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxazepam (OX) 45 mg
Trial: 6442383
Drug: Diazepam (D)
RxNorm normalized name: diazepam Injectable Solution [D-Val]
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diazepam (D) 15 mg
Trial: 6442383
Drug: Nordiazepam (ND)
RxNorm normalized name: nordazepam
DrugBank: Nordazepam (DB14028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nordiazepam (ND) 15 mg
Trial: 6442383
Drug: Diazepam (D)
RxNorm normalized name: diazepam Injectable Solution [D-Val]
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diazepam (D) 5 mg
Trial: 6442383
Drug: Oxazepam (OX)
RxNorm normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxazepam (OX) 15 mg
Trial: 6442383
Drug: Nordiazepam (ND)
RxNorm normalized name: nordazepam
DrugBank: Nordazepam (DB14028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nordiazepam (ND) 5 mg
Trial: 27075905
Drug: Vitamin B-12
RxNorm normalized name: Vitamin B-12
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B-12 intake of 1.5 μg/d (0.3, 9.7 μg/d); 60% consumed <2.4 μg/d.
Trial: 20668330
Drug: Topical cyanoacrylates
RxNorm normalized name: ethyl cyanoacrylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyanoacrylates applied every 3‐5 days for 3 months
Trial: 21079955
Drug: Topical silicone
RxNorm normalized name: silicones Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical silicone gel applied twice a day for 3 months
Trial: 11281499
Drug: 17 beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 beta‐estradiol 2 mg and norethisterone acetate 1 mg
Trial: 9065535
Drug: Average daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average daily intake of absolute alcohol 1 to 25 g/day
Trial: 9065535
Drug: Average daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average daily intake of absolute alcohol 26 to 50 g/day
Trial: 9065535
Drug: Average daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average daily intake of absolute alcohol 51 to 100 g/day
Trial: 9065535
Drug: Average daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average daily intake of absolute alcohol 101 to 200 g/day
Trial: 9065535
Drug: Average daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average daily intake of absolute alcohol >200 g/day
Trial: 20530806
Drug: Erythropoiesis-stimulating agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoiesis-stimulating agents (ESA) dose increases
Trial: 20530806
Drug: Hgb deflect(neg)
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hgb deflect(neg) and ESA dose decreases
Trial: 27846903
Drug: Proton therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton therapy with concomitant standard chemotherapy (up to 66 Gy RBE, six fractions of 2 Gy RBE per week)
Trial: 27846903
Drug: Photon therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photon therapy with concomitant standard chemotherapy (up to 66 Gy RBE, six fractions of 2 Gy RBE per week)
Trial: 24163957
Drug: Calcium-vitamin D
RxNorm normalized name: Calcium-Vitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-vitamin D supplements (500 mg carbonate calcium plus 200 IU vitamin D3) for 9 weeks
Trial: 16167418
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination (TC) cream
Trial: 9060789
Drug: Lidocaine spray
RxNorm normalized name: lidocaine Mucosal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine spray applied in the surgical wound
Trial: 9223690
Drug: Oral antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotic
Trial: 6829321
Drug: Amoxycillin 1000
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 1000 mg twice a day for three days
Trial: 6829321
Drug: Co-trimazine 90
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimazine 90 mg/sulphadiazine 410 mg, 2 tablets initially, then 1 tablet twice daily for three days
Trial: 22278631
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of leflunomide 20 mg
Trial: 22278631
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of leflunomide 20 mg
Trial: 9373419
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (CBT) for psychosis, individualised, lasting nine months
Trial: 1610419
Drug: solution gel
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL GEL [SaniClean Alcohol Antiseptic 80% Topical Solution Gel, Unscented (HP2463)]
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: solution gel (1% diclofenac)
Trial: 1610419
Drug: emulsion gel
RxNorm normalized name: propofol lipid emulsion Injection [Propoven]
DrugBank: Coconut oil (DB14322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: emulsion gel (1% diclofenac)
Trial: 3859953
Drug: Intracervical prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracervical prostaglandin gel for cervical priming
Trial: 3859953
Drug: Extra-amniotic prostaglandin
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-amniotic prostaglandin gel for labour induction
Trial: 3859953
Drug: Systemic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic administration of PG
Trial: 25891304
Drug: Nivolumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg)
Trial: 25891304
Drug: Ipilimumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (3 mg/kg) + placebo
Trial: 16455814
Drug: Sildenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (50 or 100 mg) during hypoxic exercise
Trial: 7867112
Drug: Vecuronium 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.08 mg.kg‐1 administered into the pulmonary artery
Trial: 7867112
Drug: Vecuronium 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.08 mg.kg‐1 administered into the right atrium
Trial: 7867112
Drug: Vecuronium 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.08 mg.kg‐1 administered into a peripheral vein
Trial: 2474049
Drug: Cod liver
RxNorm normalized name: Cod Liver Oil
DrugBank: Cod liver oil (DB11321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cod liver oil (20 ml d‐1 for 6 weeks)
Trial: 31285784
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day alpha-lipoic acid (ALA)
Trial: 26500082
Drug: 0.25 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 g/d EPA + DHA
Trial: 26500082
Drug: 0.5 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/d EPA + DHA
Trial: 26500082
Drug: 1.0 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g/d EPA + DHA
Trial: 22885882
Drug: Symbiotic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbiotic mixture (Probinul, 5 g bid)
Trial: 16239279
Drug: Alkalosis (NaHCO3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkalosis (NaHCO3, 0.3 g kg(‐1))
Trial: 11716995
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg tibolone (Livial, Organon)
Trial: 11716995
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 mg lactose)
Trial: 7711419
Drug: Allopurinol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (300 mg daily) from days 1-24
Trial: 7711419
Drug: Hydrochlorothiazide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (50 mg daily) from days 11-21
Trial: 7711419
Drug: Hydrochlorothiazide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (50 mg single dose) on day 43
Trial: 3415885
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine 3 or 4 ml
Trial: 3415885
Drug: 0.75% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% bupivacaine 2 or 3 ml
Trial: 3415885
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine 2 ml
Trial: 3415885
Drug: 0.75% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% bupivacaine 1.3 ml
Trial: 3415885
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dose of both solutions
Trial: 3415885
Drug: 15-20/22.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-20/22.5 mg doses
Trial: 24077970
Drug: Adherence questionnaire
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence questionnaire asking about specific antiretroviral medication
Trial: 24077970
Drug: Adherence questionnaire
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence questionnaire asking about HIV medicines as a group
Trial: 16286437
Drug: Divalproex sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex sodium at a target dose of 750 mg/day (mean dose 800 mg/day) for 6 weeks
Trial: 12402728
Drug: Early symptomatic
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early symptomatic treatment with placebo
Trial: 6107409
Drug: Zinc therapy
RxNorm normalized name: PYRITHIONE ZINC 2 g in 100 g TOPICAL SOAP [Zinc Therapy]
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc therapy (zinc chloride added to the dialysate for 6 weeks)
Trial: 28410176
Drug: SunProtect educational
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SunProtect educational program delivered through a touch-screen tablet to 84 participants.
Trial: 28410176
Drug: SunProtect educational
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SunProtect educational program delivered through a touch-screen tablet.
Trial: 17920552
Drug: Methods to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methods to steer the immune response away from cytotoxic responses or induce tolerance to gene therapy products.
Trial: 16934684
Drug: Energy restriction
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy restriction (20 kcal/kg) with whey or casein supplement (40 g/day)
Trial: 14616407
Drug: Voriconazole (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole (3 mg kg‐1) administered once daily on days 1 and 12, and every 12 h on days 3‐11 (Study A)
Trial: 14616407
Drug: Voriconazole (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole (loading dose 6 mg kg‐1 twice on day 1, then 3 mg kg‐1 twice daily on days 2‐9, and once at 3 mg kg‐1 on day 10) (Study B)
Trial: 10688417
Drug: Steroid group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid group (1 g of methylprednisolone intravenously administered two hours before operation)
Trial: 6613236
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg SIN 1
Trial: 26927501
Drug: NA (5
RxNorm normalized name: Cianocobalamina (57 Co)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NA (5 mg/d) with CEE (0.625 mg/d)
Trial: 26927501
Drug: NA (5
RxNorm normalized name: Cianocobalamina (57 Co)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NA (5 mg/d) with placebo
Trial: 21757823
Drug: hANP group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hANP group (100 μg bolus injection of hANP)
Trial: 21757823
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (physiological saline injection)
Trial: 19242495
Drug: Cladribine (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cladribine (9 mg/m² per dose) and cytarabine (500 mg/m² per day) - arm B
Trial: 19242495
Drug: Cladribine (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cladribine (9 mg/m² per dose) and cytarabine (500 mg/m² per dose) - arm A
Trial: 9354205
Drug: ACT-10 (amoxycillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-10 (amoxycillin 1000 mg b.d. + clarithromycin 500 mg b.d. + omeprazole 20 mg daily for 10 days)
Trial: 9354205
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (clarithromycin 500 mg t.d.s. + omeprazole 40 mg daily for 14 days)
Trial: 20363510
Drug: Oseltamivir (2mg/kg)
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oseltamivir (2mg/kg) given twice daily for 5 days
Trial: 17554248
Drug: Green tea-extract
RxNorm normalized name: green tea extract
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea-extract powder supplementation (544 mg polyphenols, 456 mg catechins daily for 2 months)
Trial: 1958394
Drug: Cinnarizine 3
RxNorm normalized name: cinnarizine
DrugBank: Cinnarizine (DB00568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnarizine 3 x 75 mg
Trial: 6412638
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg capsule of powdered sodium cromoglycate delivered by turbo inhaler (spinhaler)
Trial: 6412638
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of aerosolised sodium cromoglycate delivered by pressurised cannister inhaler (aerosol)
Trial: 31383853
Drug: Psychopharmacological and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychopharmacological and psychotherapeutic treatment in MARS study
Trial: 28626220
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa 500 μg subcutaneously every 3 weeks for 24 weeks
Trial: 27433865
Drug: Dance therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dance therapy (3 sessions weekly for 2 months)
Trial: 27433865
Drug: Self-care treatment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-care treatment advice (control group)
Trial: 19158002
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol colonoscopy-like preparation
Trial: 11990913
Drug: Dexanabinol (48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexanabinol (48 or 150 mg)
Trial: 11990913
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 or 3 mL vehicle)
Trial: 9641187
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (rhGH) 4 IU/m2/day for 6 months
Trial: 8120654
Drug: Low fiber
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fiber diet (15 g total dietary fiber/d)
Trial: 8120654
Drug: Diet supplemented
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet supplemented with 62 g/d of brewer's spent grain
Trial: 947448
Drug: Specially designed
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specially designed stretcher suspension system
Trial: 31919523
Drug: Low-magnitude contingency
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-magnitude contingency management (CM-L)
Trial: 23945447
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (30 mg/d, 50 mg/d, or 70 mg/d)
Trial: 18280042
Drug: Scopolamine (cholinergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (cholinergic antagonist)
Trial: 20102786
Drug: Pharmacological-induced menopause
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological-induced menopause (GnRHa treatment)
Trial: 11307807
Drug: Oral anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulants (OA)
Trial: 8300811
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone 12 IU/day